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001: From disease genes to biology, function
and therapy
Veronica van Heyningen
MRC Human Genetics Unit, Crewe Road, Edinburgh, EH4 2XU, UK
The availability of multiple eukaryotic genomic sequences has rev-
olutionized our ability to dissect the mechanisms of disease. It has
become almost commonplace to identify genes underlying single
gene anomalies; and recently genome-wide association studies have
made great strides in pinpointing genomic regions that contain vari-
ants predisposing to common multifactorial diseases. Gene
identification provides a major entre´ into the biological networks
implicated in different disease states and therefore an essential
springboard to the design of rational management regimes and ther-
apies. The genome revolution has also brought a number of other
advances. New sequencing and array technologies combined with
molecular cytogenetics allow us to identify a broader spectrum of
disease-associated mutations. Documented regulatory variation and
mutations provide novel insight into how genes work and how they
interact. Information on detailed genomic architecture and chromatin
organization make possible the systematic exploration of copy num-
ber variation. Comparative and evolutionary studies allow us to use
increasingly sophisticated model systems to understand human dis-
ease and phenotype modulation. The advent of induced pluripotential
stem cells will permit direct analysis of multiple differentiated cell
types from individuals and may ultimately lead to the development of
acceptable routes to stem cell therapies.
002: Genetics as the basic science of medicine:
but what of its practice?
Aravinda Chakravarti
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins
University, Baltimore MD 21205, USA
There has likely been no better time to be a geneticist studying the
human species. Long derided as hopelessly inadequate for genetic
investigations, owing to its long generation time and limited off-
spring size, the human is now the premier object of study. This is
not simply an anthropomorphic reaction: the wide diversity and
ecological range of humans coupled with an uncanny ability to self-
report and self-examine is the reason. Moreover, we no longer do
genetics only ‘through breeding’ but do so ‘through sequence’.
Consequently, human genetics, particularly at the molecular level
and particularly with a medical focus has gained in prominence.
Recent studies from my laboratory, in traits as diverse as Hirsch
sprung disease and sudden cardiac death, and as only one of many
examples from many laboratories, emphasize that genetics is likely
to predominate as the basic science of medicine since it provides the
most direct route to understanding pathophysiology in an unbiased
manner. The challenge is now to broadly apply what we have
already learnt over the last 50 years and what we are learning now
for the first time. This last task is more difficult than our community
lets on.
003: Synthetic biology in pursuit of low-cost, effective,
anti-malarial drugs
Jay Keasling
Center for Synthetic Biology, University of California, Berkeley,
5885 Hollis St. MC3224, Berkeley, CA 94720-3224, USA
Synthetic biology is the design and construction of new biological
entities such as enzymes, genetic circuits, and cells or the redesign of
existing biological systems. Synthetic biology builds on the advances
in molecular, cell, and systems biology and seeks to transform biol-
ogy in the same way that synthesis transformed chemistry and
integrated circuit design transformed computing. The element that
distinguishes synthetic biology from traditional molecular and cellu-
lar biology is the focus on the design and construction of core
components (parts of enzymes, genetic circuits, metabolic pathways,
etc.) that can be modeled, understood, and tuned to meet specific
performance criteria, and the assembly of these smaller parts and
devices into larger integrated systems that solve specific problems.
Just as engineers now design integrated circuits based on the known
physical properties of materials and then fabricate functioning circuits
and entire processors (with relatively high reliability), synthetic
biologists will soon design and build engineered biological systems.
We are using synthetic biology to create inexpensive, effective, anti-
malarial drugs. Currently, malaria infects 300–500 million people and
causes 1–2 million deaths each year, primarily children in Africa and
Asia. One of the principal obstacles to addressing this global health
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threat is a lack of effective, affordable drugs. The chloroquine-based
drugs that were used widely in the past have lost effectiveness
because the Plasmodium parasite which causes malaria has become
resistant to them. The faster-acting, more effective artemisinin-based
drugs—as currently produced from plant sources—are too expensive
for large-scale use in the countries where they are needed most. The
development of this technology will eventually reduce the cost of
artemisinin-based combination therapies significantly below their
current price. To reduce the cost of these drugs and make them more
widely available, we have used synthetic biology to engineer
microorganisms to produce artemisinin from renewable resources. I
will describe the process by which we engineered production of this
important drug and the prospects for translating this research to
people most in need of the drug.
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